Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747303 | 0.87 | PIK3CD (0.39) | ALDH1A1TSHRMAPK1CA7PIK3CD | |
| SCHEMBL4703289 | 0.84 | — | — | |
| SCHEMBL4705000 | 0.84 | — | — | |
| SCHEMBL18794783 | 0.84 | — | — | |
| SCHEMBL18360651 | 0.84 | — | — | |
| SCHEMBL16752078 | 0.80 | CA12 (0.50) | ALDH1A1TSHRCA7SLC6A4PIK3CD | |
| SCHEMBL17540570 | 0.80 | — | — | |
| SCHEMBL133715 | 0.79 | — | — | |
| SCHEMBL773442 | 0.79 | — | — | |
| SCHEMBL3073668 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10701932-B2 | Composition comprising dicamba and a drift control agent comprising at least one fatty alcohol | BASF SE (DE) | 2020-07-07 | — | — | US | claimed |
| US-20120279393-A1 | CO<sb>2 </sb>REMOVAL FROM GASES BY MEANS OF AQUEOUS AMINE SOLUTIONS WITH THE ADDITION OF A STERICALLY HINDERED AMINE | THYSSENKRUPP UHDE GMBH (DE) | 2012-11-08 | — | — | US | claimed |
| WO-2009109492-A1 | DYEING AUXILIARY | CLARIANT INTERNATIONAL LTD (CH) | 2009-09-11 | — | — | WO | claimed |
| US-20060293496-A1 | Process for preparing basic polycondensation products | CHT. R. BEITLICH, GMBH (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1468038-A1 | METHOD FOR PRODUCING ALKALINE POLYCONDENSATION PRODUCTS | CHT R. BEITLICH GmbH (DE) | 2004-10-20 | — | — | EP | claimed |
| WO-2003062304-A1 | METHOD FOR PRODUCING ALKALINE POLYCONDENSATION PRODUCTS | CHT R. BEITLICH GMBH (DE) | 2003-07-31 | — | — | WO | claimed |
| EP-0227562-B1 | PROCESS FOR ENCAPSULATION BY INTERFACIAL POLYADDITION | RHONE-POULENC CHIMIE (FR) | 1989-06-07 | — | — | EP | claimed |
| EP-0227562-A1 | Process for encapsulation by interfacial polyaddition | RHONE-POULENC CHIMIE (FR) | 1987-07-01 | — | — | EP | claimed |
| EP-4342927-B1 | POLYURETHANE RESIN COMPOSITION, CURED PRODUCT, ARTIFICIAL LEATHER, SYNTHETIC LEATHER, AND SURFACE TREATMENT AGENT FOR LEATHER | TOSOH CORP (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4674889-A1 | COMPOSITION AND METHOD FOR PRODUCING SAME, URETHANE RESIN, AQUEOUS URETHANE RESIN DISPERSION, AND COATING AGENT | Tosoh Corporation (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250304741-A1 | COMPOUND, METHOD FOR PRODUCING SAME, COMPOSITION, URETHANE RESIN, AQUEOUS URETHANE RESIN DISPERSION, AND COATING AGENT | TOSOH CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20250163203-A1 | POLYURETHANE RESIN COMPOSITION, ARTIFICIAL LEATHER, SYNTHETIC LEATHER, AND SURFACE TREATMENT AGENT FOR LEATHER | TOSOH CORPORATION (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4514886-A1 | RECYCLING OF POLYURETHANES BY AMINOLYSIS WITH REAGENTS COMPRISING PRIMARY AND/OR SECONDARY AND TERTIARY AMINO GROUPS IN THE STRUCTURE | Kemijski Institut (SI) | 2025-03-05 | — | — | EP | disclosed |
| EP-4495164-A1 | COMPOUND, METHOD FOR PRODUCING SAME, COMPOSITION, URETHANE RESIN, AQUEOUS URETHANE RESIN DISPERSION, AND COATING AGENT | Tosoh Corporation (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-0278878-A1 | Process for interfacial polyaddition microencapsulation | RHONE-POULENC CHIMIE (FR) | 1988-08-17 | — | — | EP | disclosed |
| EP-0227562-A1 | Process for encapsulation by interfacial polyaddition | RHONE-POULENC CHIMIE (FR) | 1987-07-01 | — | — | EP | disclosed |
| EP-0006204-B1 | AQUEOUS DISPERSIONS OF OLIGOMERIC OR POLYMERIC PLASTICS, A PROCESS FOR PREPARING SAME AND THEIR USE | BAYER AG (DE) | 1982-07-28 | — | — | EP | disclosed |
| US-4331717-A | NEUTRALIZATION OF TERTIARY NITROGEN ATOMS WITH ORGANIC ACID, CORROSION RESISTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0006204-A1 | Aqueous dispersions of oligomeric or polymeric plastics, a process for preparing same and their use | BAYER AG (DE) | 1980-01-09 | — | — | EP | disclosed |
| EP-0001086-A1 | Antimigrating agents for disperse dyes and their use in the continuous dyeing of polyester fibres | BAYER AG (DE) | 1979-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10701932-B2 | Composition comprising dicamba and a drift control agent comprising at least one fatty alcohol | DAGLA, DAGLB, DGAT1 | ALDH1A1 296/4885TSHR 2854/4885MAPK1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.